WORCESTER, Mass., Nov. 15, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Charles V. Payne and Wall Street Strategies, an independent stock market research company, have published a report on the Company. Mr. Payne is the Chief Analyst at Wall Street Strategies, and is a frequent guest on several well-respected finance-oriented radio and television programs and is widely recognized in the media as a leader in the analyst community. He is routinely sought after for his market opinions by several prestigious news organizations.
According to the report, "Less than two weeks ago, the company received approval for its delivery system, Oral-lyn in India, and the news sent the shares significantly higher. Since then, the stock has drifted lower and in our estimation makes it a screaming buy."
The report also noted that, "Management has so much passion in their fight against diabetes, bird flu, AIDS, and cancer that they haven't paid a lot of attention to the stock. Currently, Oral-lyn is in phase III testing in North America. We expect that approval would automatically make this a $5.00 stock, but once sales begin we think the stock could move even higher."
The entire report is available at http://www.wstreet.com/gnbt
Wall Street Strategies, Inc., is an independent stock market research company. The firm has successfully provided timely and effective equity advice since 1991 to money managers, brokers, and individual investors. Wall Street Strategies offers a suite of premium research products to a wide spectrum of individual, retail, and institutional clients. Charles V. Payne is the Founder, CEO and Chief Analyst of Wall Street Strategies.
Generex has entered into a consulting agreement with Wall Street Strategies to provide this report and ongoing investor relations services.
About Generex
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. In June 2007 the Company announced that patient dosing in a global Phase III clinical trial of Generex Oral-lyn(tm) will commence before year-end. For more information, visit the Generex website at http://www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.